Metraipolis › archive › dc_1507c49047fa

Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42167248
DOI
10.1016/j.xcrm.2026.102827
License (as archived)
solo-consultazione
Archived
2026-10-08T09:55:40.250Z
SHA-256 of the archived text
de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709
Stable URL of this page
https://metraipolis.com/documento/dc_1507c49047fa

How to cite

Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248 — Europe PMC (en), https://europepmc.org/article/MED/42167248 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1507c49047fa (Metraipolis archive dc_1507c49047fa, sha256 de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709)
BibTeX
@misc{dc1507c49047fa,
  title = {Biomarker study of pembrolizumab in patients with advanced rare cancers — Europe PMC PMID:42167248},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42167248},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1507c49047fa; sha256 de93ae5c59713afd5e98daef2cd46239a16412c12c4ea60d7ab138f90a857709},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42167248. Agents can read the archived copy with the MCP tool read_document.